Urinary Protein and Enzyme Excretion in Patients Receiving Chemotherapy with the Cis-platinum Analogs Carboplatin (CBDCA, JM8) and Iproplatin (CHIP, JM9)

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1988 Jan 1

PMID 3044631

Citations 4

Authors

A W Skillen

P K Buamah

B M Cantwell

C CORNELL

A W Hodson

A L Harris

Affiliations

Soon will be listed here.

Abstract

Urinary protein and enzyme excretion was measured in 33 patients with solid tumours receiving chemotherapy with the cis-platinum analogs carboplatin (JM8, CBDCA) and iproplatin (JM9, CHIP). The patients were given up to six courses of the drugs at 4-week intervals, and serial urine samples were collected weekly for periods up to 28 weeks. Overall there was no significant increase in the alkaline phosphatase (ALP), lactate dehydrogenase (LD), and N-acetyl glucosaminidase (NAG) excretion of the first posttreatment samples compared with the pretreatment samples. During the course of treatment there were transient increases in all three enzymes, some quite marked. There was no consistent increase in urinary protein or enzyme excretion during the period of treatment, suggesting that there was no cumulative nephrotoxicity. There was no change in creatinine clearance or urinary beta 2-microglobulin content. Iproplatin appeared marginally more toxic on the basis of elevated NAG and ALP during the second half of the treatment periods compared with the first (P less than 0.01 and less than 0.025, respectively).

Citing Articles

English M, Skinner R, Pearson A, Price L, Wyllie R, Craft A Br J Cancer. 1999; 81(2):336-41.

PMID: 10496362 PMC: 2362870. DOI: 10.1038/sj.bjc.6690697.

Acute and cumulative effects of carboplatin on renal function.

Sleijfer D, Smit E, Meijer S, Mulder N, Postmus P Br J Cancer. 1989; 60(1):116-20.

PMID: 2679841 PMC: 2247337. DOI: 10.1038/bjc.1989.233.

Nephrotoxicity after ifosfamide.

Skinner R, Pearson A, Price L, Coulthard M, Craft A Arch Dis Child. 1990; 65(7):732-8.

PMID: 2386379 PMC: 1792439. DOI: 10.1136/adc.65.7.732.

Investigations on the acute and chronic nephrotoxicity of the new platinum analogue carboplatin.

Kurschel E, Niederle N, Aulbert E J Cancer Res Clin Oncol. 1990; 116(2):203-6.

PMID: 2182639 DOI: 10.1007/BF01612678.

References

Goldstein R, Mayor G . Minireview. The nephrotoxicity of cisplatin. Life Sci. 1983; 32(7):685-90. DOI: 10.1016/0024-3205(83)90299-0. View

Maruhn D . Rapid colorimetric assay of beta-galactosidase and N-acetyl-beta-glucosaminidase in human urine. Clin Chim Acta. 1976; 73(3):453-61. DOI: 10.1016/0009-8981(76)90147-9. View

Diener U, Knoll E, Langer B, Rautenstrauch H, Ratge D, WISSER H . Urinary excretion of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum. Clin Chim Acta. 1981; 112(2):149-57. DOI: 10.1016/0009-8981(81)90373-9. View

Higby D, WALLACE Jr H, Albert D, HOLLAND J . Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer. 1974; 33(5):1219-5. DOI: 10.1002/1097-0142(197405)33:5<1219::aid-cncr2820330505>3.0.co;2-u. View

Hayes D, Cvitkovic E, GOLBEY R, Scheiner E, Helson L, KRAKOFF I . High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer. 1977; 39(4):1372-81. DOI: 10.1002/1097-0142(197704)39:4<1372::aid-cncr2820390404>3.0.co;2-j. View

de Gislain C, Dumas M, dAthis P, Lautissier J, ESCOUSSE A, Guerrin J . Urinary beta 2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide. Cancer Chemother Pharmacol. 1986; 18(3):276-9. DOI: 10.1007/BF00273402. View

Kuhn J, ARGY W, Rakowski T, Moriarty Jr J, SCHREINER G, Schein P . Nephrotoxicity of cis-diamminedichloroplatinum(II) as measured by urinary beta-glucuronidase. Cancer Treat Rep. 1980; 64(10-11):1083-6. View

Rose W, Schurig J, HUFTALEN J, BRADNER W . Antitumor activity and toxicity of cisplatin analogs. Cancer Treat Rep. 1982; 66(1):135-46. View

Wiltshaw E . Ovarian trials at the Royal Marsden. Cancer Treat Rev. 1985; 12 Suppl A:67-71. DOI: 10.1016/0305-7372(85)90020-9. View

10.

Fjeldborg P, Sorensen J, Helkjaer P . The long-term effect of cisplatin on renal function. Cancer. 1986; 58(10):2214-7. DOI: 10.1002/1097-0142(19861115)58:10<2214::aid-cncr2820581009>3.0.co;2-i. View

11.

Pendyala L, Madajewicz S, Lele S, Arbuck S, Creaven P . Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes. Cancer Chemother Pharmacol. 1985; 15(3):203-7. DOI: 10.1007/BF00263886. View

12.

Creaven P, Madajewicz S, Pendyala L, Mittelman A, Pontes E, Spaulding M . Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP). Cancer Treat Rep. 1983; 67(9):795-800. View

13.

Calvert A, Harland S, Newell D, Siddik Z, Jones A, McElwain T . Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982; 9(3):140-7. DOI: 10.1007/BF00257742. View

14.

Buamah P, Howell A, Whitby H, Harpur E, Gescher A . Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma. Cancer Chemother Pharmacol. 1982; 8(3):281-4. DOI: 10.1007/BF00254051. View

15.

Goren M, Forastiere A, Wright R, Horowitz M, Dodge R, Kamen B . Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. Cancer Chemother Pharmacol. 1987; 19(1):57-60. DOI: 10.1007/BF00296257. View

16.

Goren M, Wright R, Horowitz M . Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol. 1986; 18(1):69-73. DOI: 10.1007/BF00253068. View

17.

Dentino M, Luft F, Yum M, Williams S, Einhorn L . Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer. 1978; 41(4):1274-81. DOI: 10.1002/1097-0142(197804)41:4<1274::aid-cncr2820410410>3.0.co;2-f. View

18.

Hill J, Loeb E, MacLellan A, HILL N, Khan A, King J . Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep. 1975; 59(3):647-59. View

19.

Jones B, Bhalla R, Mladek J, Kaleya R, Gralla R, Alcock N . Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharmacol Ther. 1980; 27(4):557-62. DOI: 10.1038/clpt.1980.79. View

20.

Prestayko A, DAoust J, Issell B, Crooke S . Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev. 1979; 6(1):17-39. DOI: 10.1016/s0305-7372(79)80057-2. View